We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+11.07%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.52B
AUM Growth
+$425M
Cap. Flow
+$155M
Cap. Flow %
2.81%
Top 10 Hldgs %
32.71%
Holding
141
New
18
Increased
27
Reduced
28
Closed
15

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$109M
2
UTHR icon
United Therapeutics
UTHR
+$89M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$87.1M
4
BAX icon
Baxter International
BAX
+$79M
5
CI icon
Cigna
CI
+$41.9M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$57.1M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$47M
3
BLU
BELLUS Health Inc.
BLU
+$36.8M
4
PGNY icon
Progyny
PGNY
+$33.3M
5
SYK icon
Stryker
SYK
+$27.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.75%
2 Industrials 1.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
$340M 6.16%
2,718,735
– –
ISRG icon
2
Intuitive Surgical
ISRG
$128B
$212M 3.84%
620,500
– –
ELVN icon
3
Enliven Therapeutics
ELVN
$3.76B
$184M 3.33%
8,998,338
+2,125
+0% +$42.9K
BSX icon
4
Boston Scientific
BSX
$68.8B
$183M 3.31%
3,379,900
-410,100
-11% -$21.4M
THRX
5
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$161M 2.91%
17,233,668
– –
BIIB icon
6
Biogen
BIIB
$31.9B
$159M 2.87%
556,800
+51,800
+10% +$15.4M
HUM icon
7
Humana
HUM
$43.8B
$156M 2.83%
348,700
– –
BAX icon
8
Baxter International
BAX
$12.8B
$154M 2.79%
3,375,000
+1,813,000
+116% +$79M
BMRN icon
9
BioMarin Pharmaceuticals
BMRN
$12B
$140M 2.54%
1,615,210
– –
UNH icon
10
UnitedHealth
UNH
$387B
$117M 2.13%
244,000
-32,000
-12% -$15.6M
EWTX icon
11
Edgewise Therapeutics
EWTX
$4.32B
$113M 2.05%
14,567,176
– –
SLRN
12
DELISTED
ACELYRIN
SLRN
$111M 2.02%
+5,326,302
New +$109M
SWTX
13
DELISTED
SpringWorks Therapeutics
SWTX
$110M 1.99%
4,178,588
-320,312
-7% -$8.42M
IRON icon
14
Disc Medicine
IRON
$2.82B
$101M 1.83%
2,269,637
– –
BMY icon
15
Bristol-Myers Squibb
BMY
$130B
$95.2M 1.72%
1,488,000
-852,000
-36% -$57.1M
IONS icon
16
Ionis Pharmaceuticals
IONS
$9.11B
$89M 1.61%
2,169,500
+45,000
+2% +$1.73M
UTHR icon
17
United Therapeutics
UTHR
$25.9B
$88.7M 1.61%
+401,900
New +$89M
EVH icon
18
Evolent Health
EVH
$398M
$87.7M 1.59%
2,895,632
– –
VECT
19
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$87.7M 1.59%
5,156,561
– –
LLY icon
20
Eli Lilly
LLY
$1.09T
$87.2M 1.58%
186,000
– –
TMO icon
21
Thermo Fisher Scientific
TMO
$215B
$84.9M 1.54%
162,800
+15,000
+10% +$8.09M
APLS
22
DELISTED
Apellis Pharmaceuticals
APLS
$82.9M 1.5%
910,200
– –
SYK icon
23
Stryker
SYK
$134B
$82.8M 1.5%
271,400
-96,200
-26% -$27.8M
VRNA
24
DELISTED
Verona Pharma
VRNA
$79.9M 1.45%
3,777,778
-482,913
-11% -$10.3M
THC icon
25
Tenet Healthcare
THC
$22.3B
$78.2M 1.42%
960,500
-259,800
-21% -$18.5M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2023 Portfolio in Review

As of Q2 2023, OrbiMed held 141 positions worth $5.52B, up 8.3% from $5.09B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed's Q2 2023 filing shows 18 new, 27 increased, 28 reduced and 15 closed positions. Its largest new stake was ACELYRIN: 5,326,302 shares worth $111M. The largest sale was Bristol-Myers Squibb, an estimated $57.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Industrials.

  • OrbiMed's largest Q2 2023 buy was ACELYRIN: 5,326,302 shares worth $111M.
  • OrbiMed added most to Baxter International in Q2 2023, an estimated $79M increase.
  • OrbiMed's biggest Q2 2023 reduction was Bristol-Myers Squibb, cutting an estimated $57.1M.
  • OrbiMed fully exited Chinook Therapeutics, Inc. Common Stock in Q2 2023, selling an estimated $47M.
  • OrbiMed's ten largest holdings make up 33% of its $5.52B portfolio in Q2 2023.
  • OrbiMed opened 18 new positions and closed 15 in Q2 2023.
  • OrbiMed's portfolio value rose 8.3% quarter-over-quarter to $5.52B.

Based on OrbiMed's 13F filing for Q2 2023, filed 14 Aug 2023.